These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The inspection concluded with one minor observation in Form 483
The company will respond to the US FDA within the stipulated timelines
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
MRI is particularly valuable in pediatric care due to its non-invasive nature
The company is excluding data from the affected sites to maintain the study's integrity
Subscribe To Our Newsletter & Stay Updated
